• Release your full potential

    Be active. Be free. Experience superior treatment with PAD TM Technology based drugs

ABOUT US

We are committed to optimize the treatment experience and address unmet needs for patients with autoimmune and chronic inflammatory conditions through novel topical therapies tailored for fast relief of symptoms in formulations that patients prefer to use in daily routines. Read more about MC2 Therapeutics.

Platform

Our PAD™ Technology offers a number of unique advantages in the development of potent innovative new topical therapies for auto-immune and inflammatory conditions. Read more about our platform.

Pipeline

Inflammatory conditions on the skin or in the eyes may negatively affect the appearance and quality of life, why patients are highly involved in the choice of therapy. Topical therapies need to provide the three essentials in a single product: (i) High efficacy; (ii) high tolerability and (iii) high adherence (patient preference) Read more about our pipeline.

LATEST NEWS

mc2_news-image-icon-04

MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US

  • Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque ...

    READ FULL ARTICLE

MC2 Therapeutics Announces U.S. Food and Drug Administration Approval of Wynzora® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) for Adults with Plaque Psoriasis

Copenhagen, July 22nd, 2020 – MC2 Therapeutics, a commercial stage pharmaceutical company developing a new ...

READ FULL ARTICLE

 

mc2_news-image-icon-07

MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora® Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone (as dipropionate)

Copenhagen, July 16th, 2020 – MC2 Therapeutics, a commercial stage pharmaceutical company focused on topical ...

READ FULL ARTICLE

mc2_news-image-icon-04

MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head trial Comparing Wynzora™ Cream to Daivobet® Gel in Patients with Psoriasis

  • Wynzora™ Cream demonstrates statistically significantly better treatment efficacy compared to Daivobet® Gel.
  • Wynzora™ Cream demonstrates statistically ...

    READ FULL ARTICLE

© mc2 therapeutics 2020